Introduction
For the past century the classification of leukaemia has been predominantly clinical and morphological, supplemented in recent decades by the application of cytochemical techniques. During the past five to 10 years major advances in our knowledge of the nature of leukaemia consequent on the application of the techniques of immunology, cytogenetics, and molecular genetics, have taken place. Such new techniques have not only advanced knowledge but are now being applied in the diagnosis of individual patients. Information gained has led haematologists to review clinical and haematological features and to reinterpret them in the light of immunological and cytogenetic characteristics of the clone of leukaemic cells. Within the major categories of acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) many new entities have been recognised which differ in their biological features, including their prognoses. The recognition of such entities is important in using new forms of treatment which may benefit patients with leukaemias which can not be cured with current protocols.
The basis of the classification of acute leukaemia remains morphology and cytochemistry. Cases (ANAE) . SBB is at least as sensitive as MPO in detecting myeloid differentiation and has the advantage that, unlike MPO, the reaction remains positive when there has been delay in fixing the films.7 It has been suggested that SBB is less specific than MPO because positive reactions have been reported in ALL8 but we have not yet seen a positive SBB reaction in a well characterised case of ALL. The chloroacetate esterase reaction can also be used to identify myeloid cells. It is usually less sensitive than either MPO or SBB in detecting myeloid differentiation but can be useful, when combined with ANAE in a double esterase stain, for characterising leukaemia with both granulocytic and monocytic differentiation (AML M4). In identifying the monocyte lineage ANAE has a practical advantage over naphthol-AS acetate (NASA) or naphthol-ASD acetate (NASDA) esterase: it gives reactions which are weak or negative with the granulocyte lineage and the test does not therefore have to be performed with and without sodium fluoride to convey specificity. The periodic acid-Schiff (PAS) reaction is useful for supporting the diagnosis of ALL but its importance has declined as immunological markers have become more important for this purpose. PAS-block positivity, which is characteristic of ALL, correlates with the immunological phenotype, being more common in B-lineage cases. The presence of both vacuolated blasts and PAS positivity also correlates with reactivity for the common ALL antigen (CD1O).9 PAS positivity can be seen in addition in monoblasts in AML M5 and in erythroblasts in AML M6; in these lineages the positive blocks appear on a background of diffuse or finely granular positivity in contrast to the clear background of ALL. Blasts of basophil lineage may also have strong PAS positivity. Like PAS staining, the acid phosphatase reaction has declined in importance with the availability of immunological markers. A strong focal acid phosphatase activity ( Immunological markers are important in the diagnosis of acute leukaemia for many reasons. They allow: (i) a presumptive diagnosis ofALL to be confirmed by demonstration of markers of either T or B lineage; (ii) some cases which give negative reactions with SBB, MPO, and non-specific esterase to be identified as myeloid; (iii) inappropriate antigen expression and bilineage and biphenotypic leukaemia to be identified; and (iv) information which may be of prognostic importance, certainly in ALL, and possibly in AML to be gained.
The correct assignment of cases to the two major categories ofALL or AML is ofpractical importance as the drugs most likely to be effective in ALL differ from those most effective in AML, and as prophylaxis against central nervous system disease is essential in ALL and is generally not indicated in AML. Eighty to ninety per cent of cases of acute leukaemia can be correctly categorised as ALL or AML using morphology and cytochemistry alone. The addition of immunological markers allows roughly 98-99% of cases to be assigned correctly. Immunological markers are not essential in cases which can otherwise be positively identified as myeloid, but are indicated in those cases in which morphology and cytochemistry suggest ALL or do not give any clear evidence of lineage commitment. Most such cases will turn out to be ALL but a considerable minority are AML with the cells being either megakaryoblasts (AML M7), myeloblasts with minimal cytoplasmic maturation (AML MO), or blasts with the phenotype of an erythoid progenitor cell. The designation MO (M zero) is useful for cases of AML which have fewer than 3% of cells positive with SBB or an MPO stain but which can be shown by more sensitive techniques, such as electron microscopy, to show myeloid differentiation.'5 Ultrastructural morphology and cytochemistry can identify M7'6 and MO"5 AML and AML with an early erythroid phenotype,'7 but immunological typing is more widely used and more easily applicable. AML M7 can be identified with monoclonal antibodies that detect platelet glycoprotein IIIa (CD61), platelet glycoproteins IIb or IIb/IIIa (CD41), and platelet glycoproteins IX and Ib (CD42). MO AML can be identified with monoclonal antibodies of the CD13 and CD33 clusters.'5 AML with an early erythroid phenotype can be identified with monoclonal antibodies against carbonic anhydrase.'8 Erythroid cells can also be detected with monoclonal antibodies directed at the Gerbich blood group antigen (anti-Gero) or specific for glycophorin A. Also positive witherythroid cells but less specific are anti-transferrin antibodies (CD71) and antiplatelet glycoprotein IV (CD36), the latter being positive with early erythroid cells as well as with the megakaryocyte lineage.
In ALL immunological markers give information of relevance to prognosis. The worst prognosis is seen in the small minority of cases showing a mature B phenotype (surface membrane immunoglobulin positive); many such cases can also be identified morphologically because they fall into the FAB L3 category, but some B-ALL have L2 morphology and therefore can only be recognised by immunological techniques. Among other B-lineage cases a pre-B phenotype (cytoplasmic ,u chain) was found in two studies to have a worse prognosis than other non-B, non-T lineage ALL'920 but this was not observed in another study comparing the prognosis of pre-B ALL and common ALL.2' Among childhood cases of ALL T-lineage has generally been associated with a worse prognosis than B-lineage (excluding mature B) ALL, but this may not be true of adult cases in whom intensive multiagent chemotherapy has been used. with AML should be offered bone marrow transplantation. In ALL certain translocations which are also associated with Burkitt's lymphoma-t(8;14), t(2;8) and t(8;22)-are associated with a mature B phenotype, L3 morphology, and with a prognosis which has been poor in the past but which is improving with current intensive treatment protocols.37 Recently ALL with this phenotype has been recognised in AIDS. Other unfavourable karyotypes include hypodiploidy and pseudodiploidy, particularly t(9;22) with formation of the Philadelphia chromosome, t(l;1 9), and t(4; 1 1). Conversely, hyperdiploidy with more than 55 chromosomes is associated with the most favourable prognosis.
As for unfavourable immunophenotypes, the poor prognostic importance of certain chromosomal abnormalities seems to have lessened with the wider use of intensive treatment38 but cytogenetic data still remain relevant in choice of chemotherapy and in determining the appropriateness and timing of bone marrow transplantation. Relapse of leukaemia v secondary leukaemia The thorough investigation of leukaemia in relapse and of suspected secondary leukaemia is of some importance in the management of individual patients, but it is of even more importance in understanding leukaemogenesis and in determining treatment strategies for future patients. Apparent relapse should be reassessed by morphology, cytochemistry, cytogenetics and, if possible, DNA analysis in order to distinguish between relapse, with or without lineage switch, and a secondary leukaemia induced by treatment. The implication of relapse including lineage switch is that initial treatment was ineffective and may have selected for a subclone or a particular lineage, whereas the implication of a secondary leukaemia is that initial treatment has damaged DNA of residual normal stem cells and has been leukaemogenic.
Molecular genetics
When relapse of leukaemia occurs the morphological phenotype may show some changes. For example, LI ALL may relapse as L2 ALL or M2, or M4 AML as MI AML. Some change in immunological phenotype may also occur. Cytogenetic analysis usually shows an abnormal karyotype related to that present at diagnosis. Clonal evolution is common. A side-line with further karyotypic abnormality may have replaced the stem-line or may coexist with it.
When relapse is associated with a lineage switch the morphological and immunological phenotype have changed but any cytogenetic abnormality present is likely to be the same as or related to that which was present originally.
Molecular genetic analysis of TCR ,B, y, and 6
and IgJH genes shows the same rearrangement and confirms that the two leukaemias belong to the one clone as in the case described by Scott et al."9 Lineage switch may occur rapidly during induction chemotherapy in which case it is likely to indicate selection by chemotherapy. This phenomenon has been seen particularly in patients with the t(4;1 1) translocation and is an indication for change in treatment. Lineage switch may also occur at the first or subsequent relapse. Late lineage switch has commonly been from T lineage ALL to AML.
When a secondary leukaemia occurs as a result of chemotherapy administered for the primary malignancy the characteristic finding is of an AML which is often difficult to categorise morphologically with associated trilineage myelodysplasia and complex karyotypes and abnormalities of chromosomes 5 and 7 being common.43" A group of 13 children with ALL was recently described in whom a recurrence of leukaemia seemed to be secondary AML rather than a relapse, but in whom the cytogenetic features differed from those usually seen in secondary AML. 45 The original ALL was either T-or B-lineage but with T-lineage overrepresented. In nine of the 10 in whom cytogenetic analysis was performed a karyotypic abnormality was present which was not related to that present at diagnosis. In no case was there loss of material from chromosome 5 or 7 but in eight of the nine cases an abnormality with a breakpoint at l1q23 had been acquired. Further 
